Drug Farm Raises $55M in First Close of Series D Funding Round

The round also saw participation from new investors Tukar Capital, Fuzhou Xinhe Fund, Shenzhen Luohu Donghai Chempartner Investment Fund, and Keyuan Pharma. Existing investors, including BioVeda China Fund (BVCF), YD Capital, Jiashan State VC, Detong Capital, Wedo Capital, and Biometas, also participated.

The company will use the funding to advance its clinical and preclinical pipeline, speed up global clinical trials, strengthen regulatory activities in key markets, and expand its research and development capabilities.

Read More:Corner Health Closes Series A Financing Round Led by Oak HC/FT

We are pleased to welcome our new investors while receiving continued support from our long-term shareholders, reflecting strong confidence in the company's scientific innovation, development strategy and long term vision. We believe this financing positions Drug Farm to create significant value for patients, partners, and shareholders in the years ahead,” said Dr. Tian Xu, Founder and Chairman of Drug Farm.

Dr. Henri Lichenstein, Chief Executive Officer of Drug Farm, added, "We are delighted to complete this financing and grateful for the continued confidence and support from our investors. We are proud that DF-003 is amongst the first drugs developed with AI and entering a Phase 3 trial. The investment provides additional resources to advance DF-003 through the completion of a pivotal trial in patients with ROSAH syndrome and clinical proof of concept in atherosclerotic cardiovascular disease.

Dr. Tony Xu, Chief Operating Officer of Drug Farm, commented, "Powered by IDInVivo+ and MedChem5, our proprietary platforms combining genetics and artificial intelligence continues to discover and validate novel drug targets and rapidly advance multiple first-in-class candidates into the clinic.

About Drug Farm

Founded in 2015 by Tian Xu and Tony Xu, Drug Farm is a biotechnology company developing new treatments for ROSAH syndrome, heart disease, kidney disease, hepatitis B and metabolic disorders. The company uses its IDInVivo+ platform, which combines genetics and artificial intelligence, to discover and validate new drug targets.

Read More:Sunbelt Rentals Appoints Ekta Singh-Bushell to Board of Directors